Cilian AG
Cilian AG is an innovative biotechnology enterprise, which uses the unique abilities of Ciliates, a new class of production organisms, for the industrial production of therapeutic proteins. The company is working on production of vaccines, monoclonal antibodies as well as on oral enzyme preparation for the substitution therapy of pancreatic insufficiency. By using a new class of production organism (Ciliates) Cilian AG can design the production process substantially safer, more efficient and more cost-effective as this is currently possible for comparable proteins with mammalian cells. Moreover it is expected, that monoclonal antibodies can be developed and produced significantly more effective. Cilian is offering this unique technology as CIBEX-System to Pharma- and Biotech companies.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
Company Profile
Cilian is a biotechnology company that uses the unique abilities of Ciliates, a new class of production organisms, for the manufacturing at industrial scale of therapeutic proteins. Its production platform CIBEX is ideally suited for a range of viral vaccines; digestive and therapeutic enzymes; and monoclonal antibodies. Cilian is in a position to design the production process of those therapeutic proteins much more efficient, substantially safer and significantly more cost effective than other standard mammalian production methods. This should be technically and economically attractive to large pharma and biotech companies.
Business Fields
In the production of biopharmaceuticals, Cilian applies state of the art molecular biology; and genetic and process engineering methods. At the center of its CIBEX platform is the protozoan ciliate microorganism Tetrahymena thermophila. For its excellent features it is considered the “work horse” in biosciences.
In addition to the pursuit of optimizing the CIBEX platform for the general production of therapeutic enzymes, Cilian is also developing therapeutic proteins in three distinct areas: Vaccines; Enzymes and Monoclonal Antibodies.